A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 27, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Sutetinib Maleate Capsule

Oral administration

Trial Locations (9)

10016

RECRUITING

Perlmutter Cancer Center - 34th Street, New York

11042

ACTIVE_NOT_RECRUITING

Northwell Health, New Hyde Park

30607

RECRUITING

University Cancer & Blood Center (UCBC) - Athens, Athens

33612

RECRUITING

Moffitt Cancer Center, Tampa

40202

WITHDRAWN

Norton Cancer Institute - Downtown, Louisville

50309

RECRUITING

Mission Cancer + Blood - Mission Cancer Foundation, Des Moines

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

91203

WITHDRAWN

Oncology Physicians Network Healthcare, Glendale

92093

RECRUITING

University of California San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
lead

Teligene US

INDUSTRY